Compile Data Set for Download or QSAR

Found 590 hits with Last Name = 'flohr' and Initial = 's'   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kJ/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
Plasma kallikrein (Homo sapiens (Human))	BDBM212110 (US9290485, 142) Show SMILES Cc1cc(N)nc(C)c1CNC(=O)c1cnn(Cc2ccc(Cn3ccccc3=O)cc2)c1 Show InChI InChI=1S/C25H26N6O2/c1-17-11-23(26)29-18(2)22(17)13-27-25(33)21-12-28-31(16-21)15-20-8-6-19(7-9-20)14-30-10-4-3-5-24(30)32/h3-12,16H,13-15H2,1-2H3,(H2,26,29)(H,27,33)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.0224	n/a	n/a	n/a	n/a	7.8	25
NOVARTIS AG US Patent					Assay Description Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...				US Patent US9290485 (2016) BindingDB Entry DOI: 10.7270/Q26H4G73
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM212116 (US9290485, 148) Show SMILES Cc1cc(C)n(Cc2ccc(Cn3cc(nn3)C(=O)NCc3c(C)cc(N)nc3C)cc2)n1 Show InChI InChI=1S/C24H28N8O/c1-15-9-23(25)27-18(4)21(15)11-26-24(33)22-14-31(30-28-22)12-19-5-7-20(8-6-19)13-32-17(3)10-16(2)29-32/h5-10,14H,11-13H2,1-4H3,(H2,25,27)(H,26,33)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.0300	n/a	n/a	n/a	n/a	7.8	25
NOVARTIS AG US Patent					Assay Description Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...				US Patent US9290485 (2016) BindingDB Entry DOI: 10.7270/Q26H4G73
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM212114 (US9290485, 146) Show SMILES Cc1cnn(Cc2ccc(Cn3cc(cn3)C(=O)NCc3c(C)cc(N)nc3C)cc2)c1 Show InChI InChI=1S/C24H27N7O/c1-16-9-27-30(12-16)13-19-4-6-20(7-5-19)14-31-15-21(10-28-31)24(32)26-11-22-17(2)8-23(25)29-18(22)3/h4-10,12,15H,11,13-14H2,1-3H3,(H2,25,29)(H,26,32)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.0400	n/a	n/a	n/a	n/a	7.8	25
NOVARTIS AG US Patent					Assay Description Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...				US Patent US9290485 (2016) BindingDB Entry DOI: 10.7270/Q26H4G73
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM211977 (US9290485, 9) Show SMILES COc1cc(Cn2cc(cn2)C(=O)NCc2c(C)cc(N)nc2C)ccc1Cn1cccn1 Show InChI InChI=1S/C24H27N7O2/c1-16-9-23(25)29-17(2)21(16)12-26-24(32)20-11-28-31(15-20)13-18-5-6-19(22(10-18)33-3)14-30-8-4-7-27-30/h4-11,15H,12-14H2,1-3H3,(H2,25,29)(H,26,32)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.0912	n/a	n/a	n/a	n/a	7.8	25
NOVARTIS AG US Patent					Assay Description Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...				US Patent US9290485 (2016) BindingDB Entry DOI: 10.7270/Q26H4G73
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM212115 (US9290485, 147) Show SMILES Cc1ccnn1Cc1ccc(Cn2cc(nn2)C(=O)NCc2c(C)cc(N)nc2C)cc1 Show InChI InChI=1S/C23H26N8O/c1-15-10-22(24)27-17(3)20(15)11-25-23(32)21-14-30(29-28-21)12-18-4-6-19(7-5-18)13-31-16(2)8-9-26-31/h4-10,14H,11-13H2,1-3H3,(H2,24,27)(H,25,32)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.100	n/a	n/a	n/a	n/a	7.8	25
NOVARTIS AG US Patent					Assay Description Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...				US Patent US9290485 (2016) BindingDB Entry DOI: 10.7270/Q26H4G73
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM212136 (US9290485, 168) Show SMILES Cc1cc2cc(Cn3cc(cn3)C(=O)NCc3c(C)cc(N)nc3C)ccc2n1C Show InChI InChI=1S/C23H26N6O/c1-14-7-22(24)27-16(3)20(14)11-25-23(30)19-10-26-29(13-19)12-17-5-6-21-18(9-17)8-15(2)28(21)4/h5-10,13H,11-12H2,1-4H3,(H2,24,27)(H,25,30)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.100	n/a	n/a	n/a	n/a	7.8	25
NOVARTIS AG US Patent					Assay Description Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...				US Patent US9290485 (2016) BindingDB Entry DOI: 10.7270/Q26H4G73
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM212004 (US9290485, 36) Show SMILES Cc1cc(C)n(Cc2ccc(Cn3cc(cn3)C(=O)NCc3c(C)cc(N)nc3C)cc2)n1 Show InChI InChI=1S/C25H29N7O/c1-16-9-24(26)29-19(4)23(16)12-27-25(33)22-11-28-31(15-22)13-20-5-7-21(8-6-20)14-32-18(3)10-17(2)30-32/h5-11,15H,12-14H2,1-4H3,(H2,26,29)(H,27,33)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.134	n/a	n/a	n/a	n/a	7.8	25
NOVARTIS AG US Patent					Assay Description Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...				US Patent US9290485 (2016) BindingDB Entry DOI: 10.7270/Q26H4G73
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM211974 (US9290485, 6) Show SMILES Cc1cc(N)nc(C)c1CNC(=O)c1cn(Cc2ccc(Cn3cccn3)cc2)cn1 Show InChI InChI=1S/C23H25N7O/c1-16-10-22(24)28-17(2)20(16)11-25-23(31)21-14-29(15-26-21)12-18-4-6-19(7-5-18)13-30-9-3-8-27-30/h3-10,14-15H,11-13H2,1-2H3,(H2,24,28)(H,25,31)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.200	n/a	n/a	n/a	n/a	7.8	25
NOVARTIS AG US Patent					Assay Description Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...				US Patent US9290485 (2016) BindingDB Entry DOI: 10.7270/Q26H4G73
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM212134 (US9290485, 166) Show SMILES Cc1c(C)c2cc(Cn3cc(nn3)C(=O)NCc3c(C)cc(N)nc3C)ccc2n1C Show InChI InChI=1S/C23H27N7O/c1-13-8-22(24)26-15(3)19(13)10-25-23(31)20-12-30(28-27-20)11-17-6-7-21-18(9-17)14(2)16(4)29(21)5/h6-9,12H,10-11H2,1-5H3,(H2,24,26)(H,25,31)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.200	n/a	n/a	n/a	n/a	7.8	25
NOVARTIS AG US Patent					Assay Description Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...				US Patent US9290485 (2016) BindingDB Entry DOI: 10.7270/Q26H4G73
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM212135 (US9290485, 167) Show SMILES Cc1nc(N)cc(Cl)c1CNC(=O)c1cnn(Cc2ccc(Cn3ccccc3=O)cc2)c1 Show InChI InChI=1S/C24H23ClN6O2/c1-16-20(21(25)10-22(26)29-16)12-27-24(33)19-11-28-31(15-19)14-18-7-5-17(6-8-18)13-30-9-3-2-4-23(30)32/h2-11,15H,12-14H2,1H3,(H2,26,29)(H,27,33)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.200	n/a	n/a	n/a	n/a	7.8	25
NOVARTIS AG US Patent					Assay Description Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...				US Patent US9290485 (2016) BindingDB Entry DOI: 10.7270/Q26H4G73
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM212113 (US9290485, 145) Show SMILES Cc1cc(N)nc(C)c1CNC(=O)c1cnn(Cc2ccc(Cn3cccn3)cc2)c1 Show InChI InChI=1S/C23H25N7O/c1-16-10-22(24)28-17(2)21(16)12-25-23(31)20-11-27-30(15-20)14-19-6-4-18(5-7-19)13-29-9-3-8-26-29/h3-11,15H,12-14H2,1-2H3,(H2,24,28)(H,25,31)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid PDB UniChem	PDB US Patent	n/a	n/a	0.200	n/a	n/a	n/a	n/a	7.8	25
NOVARTIS AG US Patent					Assay Description Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...				US Patent US9290485 (2016) BindingDB Entry DOI: 10.7270/Q26H4G73
					More data for this Ligand-Target Pair				3D Structure (crystal)
Plasma kallikrein (Homo sapiens (Human))	BDBM212141 (US9290485, 173) Show SMILES Cc1cc(NC(=O)OC(C)(C)C)nc(C)c1CNC(=O)c1cnn(Cc2ccc3ncc(Cl)cc3c2)c1 Show InChI InChI=1S/C27H29ClN6O3/c1-16-8-24(33-26(36)37-27(3,4)5)32-17(2)22(16)13-30-25(35)20-11-31-34(15-20)14-18-6-7-23-19(9-18)10-21(28)12-29-23/h6-12,15H,13-14H2,1-5H3,(H,30,35)(H,32,33,36)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.400	n/a	n/a	n/a	n/a	7.8	25
NOVARTIS AG US Patent					Assay Description Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...				US Patent US9290485 (2016) BindingDB Entry DOI: 10.7270/Q26H4G73
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM212124 (US9290485, 156) Show SMILES Cc1ccc2cc(Cn3cc(nn3)C(=O)NCc3c(C)cc(N)nc3C)cnc2c1 Show InChI InChI=1S/C22H23N7O/c1-13-4-5-17-8-16(9-24-19(17)6-13)11-29-12-20(27-28-29)22(30)25-10-18-14(2)7-21(23)26-15(18)3/h4-9,12H,10-11H2,1-3H3,(H2,23,26)(H,25,30)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.920	n/a	n/a	n/a	n/a	7.8	25
NOVARTIS AG US Patent					Assay Description Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...				US Patent US9290485 (2016) BindingDB Entry DOI: 10.7270/Q26H4G73
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM212109 (US9290485, 141) Show SMILES Cc1cc(=O)n(C)n1Cc1ccc(Cn2cc(cn2)C(=O)NCc2c(C)cc(N)nc2C)cc1 Show InChI InChI=1S/C25H29N7O2/c1-16-9-23(26)29-18(3)22(16)12-27-25(34)21-11-28-31(15-21)13-19-5-7-20(8-6-19)14-32-17(2)10-24(33)30(32)4/h5-11,15H,12-14H2,1-4H3,(H2,26,29)(H,27,34)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	1.20	n/a	n/a	n/a	n/a	7.8	25
NOVARTIS AG US Patent					Assay Description Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...				US Patent US9290485 (2016) BindingDB Entry DOI: 10.7270/Q26H4G73
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM212125 (US9290485, 157) Show SMILES Cc1cc(N)nc(C)c1CNC(=O)c1cnn(Cc2ccc3ccc(Cl)cc3n2)c1 Show InChI InChI=1S/C22H21ClN6O/c1-13-7-21(24)27-14(2)19(13)10-25-22(30)16-9-26-29(11-16)12-18-6-4-15-3-5-17(23)8-20(15)28-18/h3-9,11H,10,12H2,1-2H3,(H2,24,27)(H,25,30)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	2	n/a	n/a	n/a	n/a	7.8	25
NOVARTIS AG US Patent					Assay Description Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...				US Patent US9290485 (2016) BindingDB Entry DOI: 10.7270/Q26H4G73
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM212122 (US9290485, 154) Show SMILES Cc1ccc2cc(Cn3cc(cn3)C(=O)NCc3c(C)cc(N)nc3C)ccc2n1 Show InChI InChI=1S/C23H24N6O/c1-14-8-22(24)28-16(3)20(14)11-25-23(30)19-10-26-29(13-19)12-17-5-7-21-18(9-17)6-4-15(2)27-21/h4-10,13H,11-12H2,1-3H3,(H2,24,28)(H,25,30)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	2	n/a	n/a	n/a	n/a	7.8	25
NOVARTIS AG US Patent					Assay Description Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...				US Patent US9290485 (2016) BindingDB Entry DOI: 10.7270/Q26H4G73
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM212062 (US9290485, 94) Show SMILES Cc1cc(N)nc(C)c1CNC(=O)c1cnn(Cc2ccc(OCc3ccccc3)cc2)c1 Show InChI InChI=1S/C26H27N5O2/c1-18-12-25(27)30-19(2)24(18)14-28-26(32)22-13-29-31(16-22)15-20-8-10-23(11-9-20)33-17-21-6-4-3-5-7-21/h3-13,16H,14-15,17H2,1-2H3,(H2,27,30)(H,28,32)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	2.10	n/a	n/a	n/a	n/a	7.8	25
NOVARTIS AG US Patent					Assay Description Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...				US Patent US9290485 (2016) BindingDB Entry DOI: 10.7270/Q26H4G73
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM212111 (US9290485, 143) Show SMILES Cc1cc(N)nc(C)c1CNC(=O)c1cnn(Cc2ccc(CN3CCCC3=O)cc2)c1 Show InChI InChI=1S/C24H28N6O2/c1-16-10-22(25)28-17(2)21(16)12-26-24(32)20-11-27-30(15-20)14-19-7-5-18(6-8-19)13-29-9-3-4-23(29)31/h5-8,10-11,15H,3-4,9,12-14H2,1-2H3,(H2,25,28)(H,26,32)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	2.60	n/a	n/a	n/a	n/a	7.8	25
NOVARTIS AG US Patent					Assay Description Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...				US Patent US9290485 (2016) BindingDB Entry DOI: 10.7270/Q26H4G73
					More data for this Ligand-Target Pair
Complement factor D (Homo sapiens (Human))	BDBM50524347 (CHEMBL4535197) Show SMILES N[C@H](CO)c1cccc(c1)-c1cc(Br)cc(COc2ccccc2CC(O)=O)c1 |r| Show InChI InChI=1S/C23H22BrNO4/c24-20-9-15(14-29-22-7-2-1-4-18(22)12-23(27)28)8-19(11-20)16-5-3-6-17(10-16)21(25)13-26/h1-11,21,26H,12-14,25H2,(H,27,28)/t21-/m1/s1	PDB KEGG UniProtKB/SwissProt B.MOAD GoogleScholar AffyNet	PC cid PC sid UniChem	Article PubMed	n/a	n/a	3	n/a	n/a	n/a	n/a	n/a	n/a
Novartis Institutes for BioMedical Research Curated by ChEMBL					Assay Description Inhibition of 2-((1E,3E,5E)-5-(1-(6-((((3S,5S)-1-((1-carbamoyl-1H-indol-3-yl)carbamoyl)-5-((3-chloro-2-fluorobenzyl)carbamoyl)-3-fluoropyrrolidin-3-y...				J Med Chem 62: 4656-4668 (2019) Article DOI: 10.1021/acs.jmedchem.9b00271 BindingDB Entry DOI: 10.7270/Q2CC144N
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM212137 (US9290485, 169) Show SMILES Cc1cn2cc(Cn3cc(cn3)C(=O)NCc3c(C)cc(N)nc3C)ccc2n1 Show InChI InChI=1S/C21H23N7O/c1-13-6-19(22)26-15(3)18(13)8-23-21(29)17-7-24-28(12-17)11-16-4-5-20-25-14(2)9-27(20)10-16/h4-7,9-10,12H,8,11H2,1-3H3,(H2,22,26)(H,23,29)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	3	n/a	n/a	n/a	n/a	7.8	25
NOVARTIS AG US Patent					Assay Description Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...				US Patent US9290485 (2016) BindingDB Entry DOI: 10.7270/Q26H4G73
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM212123 (US9290485, 155) Show SMILES Cc1cc(N)nc(C)c1CNC(=O)c1cnn(Cc2cnc3ccccc3c2)c1 Show InChI InChI=1S/C22H22N6O/c1-14-7-21(23)27-15(2)19(14)11-25-22(29)18-10-26-28(13-18)12-16-8-17-5-3-4-6-20(17)24-9-16/h3-10,13H,11-12H2,1-2H3,(H2,23,27)(H,25,29)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	3	n/a	n/a	n/a	n/a	7.8	25
NOVARTIS AG US Patent					Assay Description Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...				US Patent US9290485 (2016) BindingDB Entry DOI: 10.7270/Q26H4G73
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM212043 (US9290485, 75) Show SMILES Cc1[nH]c2ccc(Cn3cc(cn3)C(=O)NCc3c(C)cc(N)nc3C)cc2c1C Show InChI InChI=1S/C23H26N6O/c1-13-7-22(24)28-16(4)20(13)10-25-23(30)18-9-26-29(12-18)11-17-5-6-21-19(8-17)14(2)15(3)27-21/h5-9,12,27H,10-11H2,1-4H3,(H2,24,28)(H,25,30)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	3.10	n/a	n/a	n/a	n/a	7.8	25
NOVARTIS AG US Patent					Assay Description Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...				US Patent US9290485 (2016) BindingDB Entry DOI: 10.7270/Q26H4G73
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM212083 (US9290485, 115) Show SMILES Cc1cc(N)nc(C)c1CNC(=O)c1cnn(Cc2cccc(c2)-c2ccccc2)c1 Show InChI InChI=1S/C25H25N5O/c1-17-11-24(26)29-18(2)23(17)14-27-25(31)22-13-28-30(16-22)15-19-7-6-10-21(12-19)20-8-4-3-5-9-20/h3-13,16H,14-15H2,1-2H3,(H2,26,29)(H,27,31)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	3.30	n/a	n/a	n/a	n/a	7.8	25
NOVARTIS AG US Patent					Assay Description Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...				US Patent US9290485 (2016) BindingDB Entry DOI: 10.7270/Q26H4G73
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM212120 (US9290485, 152) Show SMILES CN1CCCc2ccc(Cn3cc(cn3)C(=O)NCc3c(C)cc(N)nc3C)cc12 Show InChI InChI=1S/C23H28N6O/c1-15-9-22(24)27-16(2)20(15)12-25-23(30)19-11-26-29(14-19)13-17-6-7-18-5-4-8-28(3)21(18)10-17/h6-7,9-11,14H,4-5,8,12-13H2,1-3H3,(H2,24,27)(H,25,30)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	4	n/a	n/a	n/a	n/a	7.8	25
NOVARTIS AG US Patent					Assay Description Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...				US Patent US9290485 (2016) BindingDB Entry DOI: 10.7270/Q26H4G73
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM212126 (US9290485, 158) Show SMILES Cc1cc(N)nc(C)c1CNC(=O)c1cn(Cc2ccc3ccc(Cl)cc3n2)nn1 Show InChI InChI=1S/C21H20ClN7O/c1-12-7-20(23)25-13(2)17(12)9-24-21(30)19-11-29(28-27-19)10-16-6-4-14-3-5-15(22)8-18(14)26-16/h3-8,11H,9-10H2,1-2H3,(H2,23,25)(H,24,30)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	4	n/a	n/a	n/a	n/a	7.8	25
NOVARTIS AG US Patent					Assay Description Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...				US Patent US9290485 (2016) BindingDB Entry DOI: 10.7270/Q26H4G73
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM212129 (US9290485, 161) Show SMILES Cc1cc(C)c2cc(Cn3cc(cn3)C(=O)NCc3ccc(N)nc3C)c(C)nc2c1 Show InChI InChI=1S/C24H26N6O/c1-14-7-15(2)21-9-19(17(4)28-22(21)8-14)12-30-13-20(11-27-30)24(31)26-10-18-5-6-23(25)29-16(18)3/h5-9,11,13H,10,12H2,1-4H3,(H2,25,29)(H,26,31)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	4	n/a	n/a	n/a	n/a	7.8	25
NOVARTIS AG US Patent					Assay Description Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...				US Patent US9290485 (2016) BindingDB Entry DOI: 10.7270/Q26H4G73
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM212108 (US9290485, 140) Show SMILES Cc1cc(N)nc(C)c1CNC(=O)c1cnn(Cc2ccc(Cn3ccnn3)cc2)c1 Show InChI InChI=1S/C22H24N8O/c1-15-9-21(23)27-16(2)20(15)11-24-22(31)19-10-26-30(14-19)13-18-5-3-17(4-6-18)12-29-8-7-25-28-29/h3-10,14H,11-13H2,1-2H3,(H2,23,27)(H,24,31)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	4.60	n/a	n/a	n/a	n/a	7.8	25
NOVARTIS AG US Patent					Assay Description Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...				US Patent US9290485 (2016) BindingDB Entry DOI: 10.7270/Q26H4G73
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM212107 (US9290485, 139) Show SMILES Cc1cc(N)nc(C)c1CNC(=O)c1cnn(Cc2ccc(Cn3ccc(=O)[nH]3)cc2)c1 Show InChI InChI=1S/C23H25N7O2/c1-15-9-21(24)27-16(2)20(15)11-25-23(32)19-10-26-30(14-19)13-18-5-3-17(4-6-18)12-29-8-7-22(31)28-29/h3-10,14H,11-13H2,1-2H3,(H2,24,27)(H,25,32)(H,28,31)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	4.90	n/a	n/a	n/a	n/a	7.8	25
NOVARTIS AG US Patent					Assay Description Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...				US Patent US9290485 (2016) BindingDB Entry DOI: 10.7270/Q26H4G73
					More data for this Ligand-Target Pair
Complement factor D (Homo sapiens (Human))	BDBM50462108 (CHEMBL4246585) Show SMILES N[C@H](CO)c1cccc(c1)-c1cc(CO)cc(COc2ccccc2CC(O)=O)c1 |r| Show InChI InChI=1S/C24H25NO5/c25-22(14-27)19-6-3-5-18(11-19)21-9-16(13-26)8-17(10-21)15-30-23-7-2-1-4-20(23)12-24(28)29/h1-11,22,26-27H,12-15,25H2,(H,28,29)/t22-/m1/s1	PDB KEGG UniProtKB/SwissProt B.MOAD GoogleScholar AffyNet	PC cid PC sid UniChem	Article PubMed	n/a	n/a	5	n/a	n/a	n/a	n/a	n/a	n/a
Novartis Institutes for BioMedical Research Curated by ChEMBL					Assay Description Inhibition of 2-((1E,3E,5E)-5-(1-(6-((((3S,5S)-1-((1-carbamoyl-1H-indol-3-yl)carbamoyl)-5-((3-chloro-2-fluorobenzyl)carbamoyl)-3-fluoropyrrolidin-3-y...				J Med Chem 62: 4656-4668 (2019) Article DOI: 10.1021/acs.jmedchem.9b00271 BindingDB Entry DOI: 10.7270/Q2CC144N
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM212131 (US9290485, 163) Show SMILES COc1ccc2cc(Cn3cc(cn3)C(=O)NCc3c(C)cc(N)nc3C)ccc2c1 Show InChI InChI=1S/C24H25N5O2/c1-15-8-23(25)28-16(2)22(15)12-26-24(30)20-11-27-29(14-20)13-17-4-5-19-10-21(31-3)7-6-18(19)9-17/h4-11,14H,12-13H2,1-3H3,(H2,25,28)(H,26,30)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	5	n/a	n/a	n/a	n/a	7.8	25
NOVARTIS AG US Patent					Assay Description Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...				US Patent US9290485 (2016) BindingDB Entry DOI: 10.7270/Q26H4G73
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM212130 (US9290485, 162) Show SMILES Cc1cc(N)nc(C)c1CNC(=O)c1cnn(Cc2cc(c3cc(F)ccc3n2)C(F)(F)F)c1 Show InChI InChI=1S/C23H20F4N6O/c1-12-5-21(28)31-13(2)18(12)9-29-22(34)14-8-30-33(10-14)11-16-7-19(23(25,26)27)17-6-15(24)3-4-20(17)32-16/h3-8,10H,9,11H2,1-2H3,(H2,28,31)(H,29,34)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	5	n/a	n/a	n/a	n/a	7.8	25
NOVARTIS AG US Patent					Assay Description Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...				US Patent US9290485 (2016) BindingDB Entry DOI: 10.7270/Q26H4G73
					More data for this Ligand-Target Pair
Complement factor D (Homo sapiens (Human))	BDBM171332 (US9085555, 762) Show SMILES NC(=O)n1cc(NC(=O)N2[C@@H]3C[C@@H]3C[C@H]2C(=O)Nc2cccc(Br)n2)c2ccccc12 |r| Show InChI InChI=1S/C21H19BrN6O3/c22-17-6-3-7-18(25-17)26-19(29)16-9-11-8-15(11)28(16)21(31)24-13-10-27(20(23)30)14-5-2-1-4-12(13)14/h1-7,10-11,15-16H,8-9H2,(H2,23,30)(H,24,31)(H,25,26,29)/t11-,15-,16+/m1/s1	PDB KEGG UniProtKB/SwissProt B.MOAD GoogleScholar AffyNet	PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	6	n/a	n/a	n/a	n/a	n/a	n/a
Novartis Pharma AG Curated by ChEMBL					Assay Description Inhibition of recombinant human complement factor D catalytic domain using Z-Lys-thiobenzylester as substrate preincubated for 1 hr followed by subst...				J Med Chem 60: 5717-5735 (2017) Article DOI: 10.1021/acs.jmedchem.7b00425 BindingDB Entry DOI: 10.7270/Q2TB195V
					More data for this Ligand-Target Pair
Complement factor D (Homo sapiens (Human))	BDBM171332 (US9085555, 762) Show SMILES NC(=O)n1cc(NC(=O)N2[C@@H]3C[C@@H]3C[C@H]2C(=O)Nc2cccc(Br)n2)c2ccccc12 |r| Show InChI InChI=1S/C21H19BrN6O3/c22-17-6-3-7-18(25-17)26-19(29)16-9-11-8-15(11)28(16)21(31)24-13-10-27(20(23)30)14-5-2-1-4-12(13)14/h1-7,10-11,15-16H,8-9H2,(H2,23,30)(H,24,31)(H,25,26,29)/t11-,15-,16+/m1/s1	PDB KEGG UniProtKB/SwissProt B.MOAD GoogleScholar AffyNet	PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	6	n/a	n/a	n/a	n/a	n/a	n/a
Novartis Pharma AG Curated by ChEMBL					Assay Description Inhibition of recombinant human complement factor D catalytic domain using Z-Lys-thiobenzylester as substrate preincubated for 1 hr followed by subst...				J Med Chem 60: 5717-5735 (2017) Article DOI: 10.1021/acs.jmedchem.7b00425 BindingDB Entry DOI: 10.7270/Q2TB195V
					More data for this Ligand-Target Pair
Complement factor B (Homo sapiens (Human))	BDBM50540314 (CHEMBL4639592) Show SMILES CCO[C@H]1CCN(Cc2c(cc(C)c3[nH]ccc23)C2CC2)[C@@H](C1)c1ccc(cc1)C(O)=O |r| Show InChI InChI=1S/C27H32N2O3/c1-3-32-21-11-13-29(25(15-21)19-6-8-20(9-7-19)27(30)31)16-24-22-10-12-28-26(22)17(2)14-23(24)18-4-5-18/h6-10,12,14,18,21,25,28H,3-5,11,13,15-16H2,1-2H3,(H,30,31)/t21-,25-/m0/s1	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	Article PubMed	n/a	n/a	6	n/a	n/a	n/a	n/a	n/a	n/a
Novartis Institutes for BioMedical Research Curated by ChEMBL					Assay Description Inhibition of human serine protease factor B by TR-FRET based competition binding assay				J Med Chem 63: 5697-5722 (2020) Article DOI: 10.1021/acs.jmedchem.9b01870 BindingDB Entry DOI: 10.7270/Q21N84P4
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM212133 (US9290485, 165) Show SMILES Cc1nc2cc(Cn3cc(cn3)C(=O)NCc3c(C)cc(N)nc3C)ccc2n1C Show InChI InChI=1S/C22H25N7O/c1-13-7-21(23)26-14(2)18(13)10-24-22(30)17-9-25-29(12-17)11-16-5-6-20-19(8-16)27-15(3)28(20)4/h5-9,12H,10-11H2,1-4H3,(H2,23,26)(H,24,30)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	6	n/a	n/a	n/a	n/a	7.8	25
NOVARTIS AG US Patent					Assay Description Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...				US Patent US9290485 (2016) BindingDB Entry DOI: 10.7270/Q26H4G73
					More data for this Ligand-Target Pair
Complement factor D (Homo sapiens (Human))	BDBM256239 (US9487483, 91) Show SMILES CC(=O)c1nn(CC(=O)N2[C@@H]3C[C@@H]3C[C@H]2C(=O)N[C@@H]2CCCC(Cl)(Cl)C2)c2ccccc12 |r| Show InChI InChI=1S/C23H26Cl2N4O3/c1-13(30)21-16-6-2-3-7-17(16)28(27-21)12-20(31)29-18-9-14(18)10-19(29)22(32)26-15-5-4-8-23(24,25)11-15/h2-3,6-7,14-15,18-19H,4-5,8-12H2,1H3,(H,26,32)/t14-,15-,18-,19+/m1/s1	PDB KEGG UniProtKB/SwissProt B.MOAD GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	6	n/a	n/a	n/a	n/a	7.5	25
Novartis AG US Patent					Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...				US Patent US9487483 (2016) BindingDB Entry DOI: 10.7270/Q2R78D53
					More data for this Ligand-Target Pair
Complement factor D [24-253] (Homo sapiens (Human))	BDBM171350 (1-(2-((1R,3S,5R)-3-((6-Bromopyridin-2-yl)carbamoyl...) Show SMILES NC(=O)c1nn(CC(=O)N2[C@@H]3C[C@@H]3C[C@H]2C(=O)Nc2cccc(Br)n2)c2ccccc12 Show InChI InChI=1S/C21H19BrN6O3/c22-16-6-3-7-17(24-16)25-21(31)15-9-11-8-14(11)28(15)18(29)10-27-13-5-2-1-4-12(13)19(26-27)20(23)30/h1-7,11,14-15H,8-10H2,(H2,23,30)(H,24,25,31)/t11-,14-,15+/m1/s1	PDB UniProtKB/SwissProt GoogleScholar AffyNet	Purchase MCE PC cid PC sid PDB UniChem Similars	PDB Article PubMed	n/a	n/a	6	n/a	n/a	n/a	n/a	7.5	25
Novartis Pharma AG					Assay Description Briefly, recombinant human or murine FD catalytic domain (10 nM concentration) were incubated with compound at various concentrations for 1 h at room...				Nat Chem Biol 12: 1105-1110 (2016) Article DOI: 10.1038/nchembio.2208 BindingDB Entry DOI: 10.7270/Q2KD1WR1
					More data for this Ligand-Target Pair				3D Structure (crystal)
Plasma kallikrein (Homo sapiens (Human))	BDBM212057 (US9290485, 89) Show SMILES Cc1cc(N)nc(C)c1CNC(=O)c1cnn(Cc2ccc(COc3ccccc3)cc2)c1 Show InChI InChI=1S/C26H27N5O2/c1-18-12-25(27)30-19(2)24(18)14-28-26(32)22-13-29-31(16-22)15-20-8-10-21(11-9-20)17-33-23-6-4-3-5-7-23/h3-13,16H,14-15,17H2,1-2H3,(H2,27,30)(H,28,32)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	6	n/a	n/a	n/a	n/a	7.8	25
NOVARTIS AG US Patent					Assay Description Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...				US Patent US9290485 (2016) BindingDB Entry DOI: 10.7270/Q26H4G73
					More data for this Ligand-Target Pair
Complement factor D (Homo sapiens (Human))	BDBM249390 (US9464081, 22) Show SMILES [#6]-[#6@@H](-[#7]-[#6](=O)-[#6@@H]-1-[#6]-[#6@H]-2-[#6]-[#6@H]-2-[#7]-1-[#6](=O)-[#6]-n1nc(-[#6](-[#7])=O)c2ccccc12)-[#6](\F)=[#6](\[#6])-[#6] |r| Show InChI InChI=1S/C22H26FN5O3/c1-11(2)19(23)12(3)25-22(31)17-9-13-8-16(13)28(17)18(29)10-27-15-7-5-4-6-14(15)20(26-27)21(24)30/h4-7,12-13,16-17H,8-10H2,1-3H3,(H2,24,30)(H,25,31)/t12-,13-,16-,17+/m1/s1	PDB KEGG UniProtKB/SwissProt B.MOAD GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	6	n/a	n/a	n/a	n/a	7.5	25
Novartis AG US Patent					Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...				US Patent US9464081 (2016) BindingDB Entry DOI: 10.7270/Q2PN94K2
					More data for this Ligand-Target Pair
Complement factor D (Homo sapiens (Human))	BDBM249383 (US9464081, 16) Show SMILES [#6]\[#6](-[#6])=[#6](/F)-[#6]-[#7]-[#6](=O)-[#6@@H]-1-[#6]-[#6@H]-2-[#6]-[#6@H]-2-[#7]-1-[#6](=O)-[#6]-n1nc(-[#6](-[#6])=O)c2cc(-[#8]-[#6]-c3ncccn3)ccc12 |r| Show InChI InChI=1S/C27H29FN6O4/c1-15(2)20(28)12-31-27(37)23-10-17-9-22(17)34(23)25(36)13-33-21-6-5-18(11-19(21)26(32-33)16(3)35)38-14-24-29-7-4-8-30-24/h4-8,11,17,22-23H,9-10,12-14H2,1-3H3,(H,31,37)/t17-,22-,23+/m1/s1	PDB KEGG UniProtKB/SwissProt B.MOAD GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	7	n/a	n/a	n/a	n/a	7.5	25
Novartis AG US Patent					Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...				US Patent US9464081 (2016) BindingDB Entry DOI: 10.7270/Q2PN94K2
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM212127 (US9290485, 159) Show SMILES Cc1ccc2cc(Cn3cc(cn3)C(=O)NCc3ccc(N)nc3C)ccc2n1 Show InChI InChI=1S/C22H22N6O/c1-14-3-5-17-9-16(4-7-20(17)26-14)12-28-13-19(11-25-28)22(29)24-10-18-6-8-21(23)27-15(18)2/h3-9,11,13H,10,12H2,1-2H3,(H2,23,27)(H,24,29)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	7	n/a	n/a	n/a	n/a	7.8	25
NOVARTIS AG US Patent					Assay Description Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...				US Patent US9290485 (2016) BindingDB Entry DOI: 10.7270/Q26H4G73
					More data for this Ligand-Target Pair
Complement factor D (Homo sapiens (Human))	BDBM249386 (US9464081, 19) Show SMILES [#6]-[#6](-[#7]-[#6](=O)-[#6@@H]-1-[#6]-[#6@H]-2-[#6]-[#6@H]-2-[#7]-1-[#6](=O)-[#6]-n1nc(-[#6](-[#7])=O)c2ccccc12)-[#6](\F)=[#6](\[#6])-[#6] |r| Show InChI InChI=1S/C22H26FN5O3/c1-11(2)19(23)12(3)25-22(31)17-9-13-8-16(13)28(17)18(29)10-27-15-7-5-4-6-14(15)20(26-27)21(24)30/h4-7,12-13,16-17H,8-10H2,1-3H3,(H2,24,30)(H,25,31)/t12?,13-,16-,17+/m1/s1	PDB KEGG UniProtKB/SwissProt B.MOAD GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	7	n/a	n/a	n/a	n/a	7.5	25
Novartis AG US Patent					Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...				US Patent US9464081 (2016) BindingDB Entry DOI: 10.7270/Q2PN94K2
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM212117 (US9290485, 149) Show SMILES Cc1nc(N)cc(OCC(=O)C(C)(C)C)c1CNC(=O)c1cnn(Cc2ccc3ccccc3c2)c1 Show InChI InChI=1S/C28H31N5O3/c1-18-23(24(12-26(29)32-18)36-17-25(34)28(2,3)4)14-30-27(35)22-13-31-33(16-22)15-19-9-10-20-7-5-6-8-21(20)11-19/h5-13,16H,14-15,17H2,1-4H3,(H2,29,32)(H,30,35)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	7.80	n/a	n/a	n/a	n/a	7.8	25
NOVARTIS AG US Patent					Assay Description Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...				US Patent US9290485 (2016) BindingDB Entry DOI: 10.7270/Q26H4G73
					More data for this Ligand-Target Pair
Complement factor D (Homo sapiens (Human))	BDBM50524338 (CHEMBL4468000) Show SMILES NCc1cccc(c1)-c1cccc(COc2ccccc2CC(O)=O)c1 Show InChI InChI=1S/C22H21NO3/c23-14-16-5-3-8-18(11-16)19-9-4-6-17(12-19)15-26-21-10-2-1-7-20(21)13-22(24)25/h1-12H,13-15,23H2,(H,24,25)	PDB KEGG UniProtKB/SwissProt B.MOAD GoogleScholar AffyNet	PC cid PC sid UniChem	Article PubMed	n/a	n/a	8	n/a	n/a	n/a	n/a	n/a	n/a
Novartis Institutes for BioMedical Research Curated by ChEMBL					Assay Description Inhibition of 2-((1E,3E,5E)-5-(1-(6-((((3S,5S)-1-((1-carbamoyl-1H-indol-3-yl)carbamoyl)-5-((3-chloro-2-fluorobenzyl)carbamoyl)-3-fluoropyrrolidin-3-y...				J Med Chem 62: 4656-4668 (2019) Article DOI: 10.1021/acs.jmedchem.9b00271 BindingDB Entry DOI: 10.7270/Q2CC144N
					More data for this Ligand-Target Pair
Complement factor D (Homo sapiens (Human))	BDBM50524344 (CHEMBL4584532) Show SMILES CC(C)(O)c1cc(COc2ccccc2CC(O)=O)cc(c1)-c1cccc(c1)[C@H](N)CO |r| Show InChI InChI=1S/C26H29NO5/c1-26(2,31)22-11-17(16-32-24-9-4-3-6-20(24)14-25(29)30)10-21(13-22)18-7-5-8-19(12-18)23(27)15-28/h3-13,23,28,31H,14-16,27H2,1-2H3,(H,29,30)/t23-/m1/s1	PDB KEGG UniProtKB/SwissProt B.MOAD GoogleScholar AffyNet	PC cid PC sid UniChem	Article PubMed	n/a	n/a	8	n/a	n/a	n/a	n/a	n/a	n/a
Novartis Institutes for BioMedical Research Curated by ChEMBL					Assay Description Inhibition of 2-((1E,3E,5E)-5-(1-(6-((((3S,5S)-1-((1-carbamoyl-1H-indol-3-yl)carbamoyl)-5-((3-chloro-2-fluorobenzyl)carbamoyl)-3-fluoropyrrolidin-3-y...				J Med Chem 62: 4656-4668 (2019) Article DOI: 10.1021/acs.jmedchem.9b00271 BindingDB Entry DOI: 10.7270/Q2CC144N
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM211991 (US9290485, 23) Show SMILES Cc1cc(N)nc(C)c1CNC(=O)c1cn(Cc2ccc(Oc3ccccc3)cc2)cn1 Show InChI InChI=1S/C25H25N5O2/c1-17-12-24(26)29-18(2)22(17)13-27-25(31)23-15-30(16-28-23)14-19-8-10-21(11-9-19)32-20-6-4-3-5-7-20/h3-12,15-16H,13-14H2,1-2H3,(H2,26,29)(H,27,31)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	9	n/a	n/a	n/a	n/a	7.8	25
NOVARTIS AG US Patent					Assay Description Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...				US Patent US9290485 (2016) BindingDB Entry DOI: 10.7270/Q26H4G73
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM212008 (US9290485, 40) Show SMILES Cc1cc(N)nc(C)c1CNC(=O)c1cn(Cc2ccc3ccccc3c2)nn1 Show InChI InChI=1S/C22H22N6O/c1-14-9-21(23)25-15(2)19(14)11-24-22(29)20-13-28(27-26-20)12-16-7-8-17-5-3-4-6-18(17)10-16/h3-10,13H,11-12H2,1-2H3,(H2,23,25)(H,24,29)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	9	n/a	n/a	n/a	n/a	7.8	25
NOVARTIS AG US Patent					Assay Description Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...				US Patent US9290485 (2016) BindingDB Entry DOI: 10.7270/Q26H4G73
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM212099 (US9290485, 131) Show SMILES Cc1cc(N)nc(C)c1CNC(=O)c1ccn(c1)S(=O)(=O)c1ccc2n(C)ccc2c1 Show InChI InChI=1S/C22H23N5O3S/c1-14-10-21(23)25-15(2)19(14)12-24-22(28)17-7-9-27(13-17)31(29,30)18-4-5-20-16(11-18)6-8-26(20)3/h4-11,13H,12H2,1-3H3,(H2,23,25)(H,24,28)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	9	n/a	n/a	n/a	n/a	7.8	25
NOVARTIS AG US Patent					Assay Description Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...				US Patent US9290485 (2016) BindingDB Entry DOI: 10.7270/Q26H4G73
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM212138 (US9290485, 170) Show SMILES Cc1ccc2cc(Cc3nc(co3)C(=O)NCc3c(C)cc(N)nc3C)ccc2n1 Show InChI InChI=1S/C23H23N5O2/c1-13-8-21(24)27-15(3)18(13)11-25-23(29)20-12-30-22(28-20)10-16-5-7-19-17(9-16)6-4-14(2)26-19/h4-9,12H,10-11H2,1-3H3,(H2,24,27)(H,25,29)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	9.70	n/a	n/a	n/a	n/a	7.8	25
NOVARTIS AG US Patent					Assay Description Enzymatic reactions were conducted in ⿿assay buffer⿿, comprising 50 mM Hepes/NaOH at pH 7.8, 150 mM NaCl, 1 mM EDTA and 0.05% (w/v) CHAPS. For th...				US Patent US9290485 (2016) BindingDB Entry DOI: 10.7270/Q26H4G73
					More data for this Ligand-Target Pair
Complement factor D (Homo sapiens (Human))	BDBM171239 (US9085555, 669) Show SMILES NC(=O)c1nn(CC(=O)N2[C@@H]3C[C@@H]3C[C@H]2C(=O)Nc2cccc(Br)c2F)c2ccccc12 |r| Show InChI InChI=1S/C22H19BrFN5O3/c23-13-5-3-6-14(19(13)24)26-22(32)17-9-11-8-16(11)29(17)18(30)10-28-15-7-2-1-4-12(15)20(27-28)21(25)31/h1-7,11,16-17H,8-10H2,(H2,25,31)(H,26,32)/t11-,16-,17+/m1/s1	PDB KEGG UniProtKB/SwissProt B.MOAD GoogleScholar AffyNet	PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	10	n/a	n/a	n/a	n/a	n/a	n/a
Novartis Pharma AG Curated by ChEMBL					Assay Description Inhibition of recombinant human complement factor D catalytic domain using Z-Lys-thiobenzylester as substrate preincubated for 1 hr followed by subst...				J Med Chem 60: 5717-5735 (2017) Article DOI: 10.1021/acs.jmedchem.7b00425 BindingDB Entry DOI: 10.7270/Q2TB195V
					More data for this Ligand-Target Pair

Displayed 1 to 50 (of 590 total )  |  Next  |  Last  >>

Jump to: